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Highlights 
 FP-E6F47RCP and FP-E7GGGCP correctly express transgenes in different cell lines 
 After the genetic immunization, tumor volume was lower than in the control mice 
 Genetic immunization delayed tumor appearance compared to control mice 
 After DNA/FP vaccination, better results were obtained by E6/E7 single immunogens 
 
 
Abstract 
The therapeutic antitumor potency of a prime–boost vaccination strategy was explored, based on the 
mutated, nontransforming forms of the E6 (E6F47R) and E7 (E7GGG) oncogenes of Human Papilloma Virus 
type 16 (HPV16), fused to the Potato virus X (PVX) coat protein (CP) sequence. Previous data showed that 
CP fusion improves the immunogenicity of tumor-associated antigens and may thus increase their efficacy. 
After verifying the correct expression of  E6F47RCP and E7GGGCP inserted into DNA and Fowlpox virus 
recombinants by Western blotting and immunofluorescence, their combined use was evaluated for therapy in 
a pre-clinical mouse model of HPV16-related tumorigenicity. Immunization protocols were applied using 
homologous (DNA/DNA) or heterologous (DNA/Fowlpox) prime–boost vaccine regimens. The humoral 
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immune responses were determined by ELISA, and the therapeutic efficacy evaluated by the delay in tumor 
appearance and reduced tumor volume after inoculation of syngeneic TC-1* tumor cells. Homologous 
DNA/DNA genetic vaccines were able to better delay tumor appearance and inhibit tumor growth when 
DNAE6F47RCP and DNAE7GGGCP were administered in combination. However, the heterologous 
DNA/Fowlpox vaccination strategy was able to delay tumor appearance in a higher number of animals when 
E6F47RCP and in particular E7GGGCP were administered alone.  
 
 
Keywords: HPV therapeutic vaccines; Fowlpox virus recombinants; prime/boost immunizations; Potato 
virus X coat protein; E6 and E7 modified oncoproteins 
 
 
 
1. Introduction 
The Human Papilloma Virus (HPV) is responsible for more than 550,000 new cases of human cancers each 
year, and the high-risk HPV16 and HPV18 genotypes represent the primary etiologic agents of cervical 
tumors (Roden and Wu, 2003). HPV16 and HPV18 are also implicated in the majority of the ano-genital 
tumors of both sexes (Zandberg et al., 2013) and in a subset of head and neck cancers (Worsham et al., 
2012). After infection, the E6 and E7 oncoproteins of HPV16 bind and interact with specific cell substrates 
to generate an immune environment that cannot control tumorigenicity and contributes to cancer initiation 
and progression (Münger et al., 1989; Song et al., 2000). In particular, E6 and E7 deregulate fundamental 
cellular events, such as the cell cycle, apoptosis, DNA repair, cell senescence and differentiation (Duensing 
and Münger, 2004; Hudson et al., 1990). Although effective prophylactic vaccines have been introduced to 
prevent high-risk HPV infection and the development of cervical tumors, the therapeutic efforts to annihilate 
HPV-associated diseases still remain a critical issue (Knoff et al., 2014). On this basis, both DNA expression 
plasmids and viral-vectored immunogens have many inherent features that make them promising vaccine 
candidates.  
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Genetic vaccines can elicit good immune responses, and they are relatively stable, inexpensive, susceptible 
to genetic manipulations, and safe also for immunocompromised individuals, as they do not contain live or 
inactivated pathogens (Gurunathan et al., 2000). Recently, a bivalent therapeutic vaccine (VGX-3100) 
showed efficacy against HPV16 and HPV18, thus offering a possible option for the prevention of cervical 
cancer by eliciting HPV-specific immunity. Also, in a phase III efficacy trial, the novel 9-valent HPV 
prophylactic vaccine (9vHPV) demonstrated 96.7% efficacy against vulvar and vaginal intraepithelial 
neoplasia grade 2 or 3, caused by HPV31, HPV33, HPV45, HPV52, or HPV58 (Livermore, 1995). 
However, preclinical studies have already demonstrated that DNA-based vaccines encoding the E6 or the E7 
proteins are less immunogenic and effective than those in which these oncogenes are fused to carriers (Knoff 
et al., 2014; Rosales and Rosales, 2014). Carriers can improve antigen presentation and tumor eradication, 
and they include calreticulin (Peng et al., 2004), Mycobacterium tuberculosis heat-shock protein-70, Herpes 
simplex virus type 1 (HSV-1) VP22 protein and lysosome-associated membrane protein-1 (Peng et al., 
2005), Escherichia coli β-glucuronidase (Poláková et al., 2010), tetanus toxin fragment C (Oosterhuis et al., 
2011), and Simian virus 40 J-domain and enhancer (Almajhdi et al., 2014). Moreover, as a general 
drawback, DNA vaccines show low immunogenicity and efficacy in nonhuman and human primates (Pereira 
et al., 2014), and it can be important to know whether immunogenicity can be enhanced by boosting with 
poxvirus-based recombinants also when DNA priming is performed only once. 
Vaccinia virus-based recombinants have already been used successfully to enhance antigen immunogenicity 
in prime–boost protocols, where they were primed by DNA-based E6/E7 genetic vaccines (Chen et al., 
2000; Mackova  et al., 2006). However, to limit the induction of neutralizing antibodies against this 
replicative vector, alternative safe non-replicative poxvirus vectors are under evaluation, which can also 
overcome the only partially abortive replication in mammals of the Modified Vaccinia virus Ankara 
(Blanchard et al., 1998; Drexler et al., 1998). With this aim, a non-pathogenic Fowlpox virus (FP) poultry 
vaccine strain has already been engineered as a recombinant vector against different human infectious 
diseases, and it has also been used in pre-clinical studies for HPV (Radaelli et al., 2012). Avian poxviruses 
are replication-restricted to avian species (Taylor and Paoletti, 1988) and they do not cross-react 
immunologically with mammalian poxviruses. They can elicit a complete immune response in vaccinated 
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hosts (Zanotto et al., 2010), and can escape pre-existing immunity in smallpox-experienced humans. They 
thus represent safe immunogens that are permissive for entry and transgene expression in most mammalian 
cells (Bissa et al., 2013; Pacchioni et al., 2013). In particular, FP has recently received the approval for 
clinical use in humans (www.ClinicalTrials.gov Identifier: NCT00083603), and FP-based recombinants 
combined with DNA in prime–boost immunization regimens have already shown greater protection when 
mice were primed with DNA followed by a FP boost (Radaelli et al., 2007). Although immune responses to 
HPV-related tumors include antibodies and TNF-(Frazer et al., 2004; Malejczyk et al., 1992), tumor cells 
can be mainly eliminated by antigen-specific cytotoxic T-lymphocytes (Frazer et al., 2011; Li et al., 2010) 
and heterologous prime–boost regimens are among the most potent strategies to induce a cell-mediated 
immunity (Anderson and Schneider, 2007). The use of plasmid DNA combined with FP recombinant 
vaccines to deliver tumor-specific antigens might thus overcome the low immunogenicity of E6 and E7.  
In our previous study, DNA and FP recombinants were generated that expressed a mutant HPV16 E6 
antigen (E6F47R) defective for the degradation of the p53 cell substrate. These recombinants were evaluated 
in preventive and therapeutic immunization protocols using a pre-clinical mouse model and following 
prime–boost vaccination regimens (Bissa et al., 2015). The results established a preliminary indication for 
the use of DNA and FP-based constructs as safe and effective immunogens, but also the necessity to 
improve their immunogenicity to enhance their antitumor efficacy.  
Antigen fusion strategies increase vaccine stimulation of T cells that have escaped tolerance mechanisms 
and might have a particular potential for immunotherapy (Massa et al., 2008). DNA vaccines that encoded 
the HPV16 E5, E6 and E7 proteins genetically fused to HSV-1 glycoprotein D have already shown 
promising results in the control of cervical cancer in the preclinical mouse model (Diniz et al., 2010). 
However, neutralizing antibodies that target the glycoprotein D region required for the vaccine efficacy were 
reported in HSV-1-seropositive humans (Whitbeck et al., 1999). On this basis, the new class of plant-virus-
derived sequences of the Potato virus X (PVX) coat protein (CP) can be a suitable carrier for antigen 
display. CP is recognized as a good immunogen for humans, and it can aggregate into structures that can 
increase CD4+ T-cell–mediated protection (Savelyeva et al., 2001; Savelyeva et al., 2003). PVX and PVX-
CP have already been fused to different viral antigens for transient expression in plant and epitope-
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presentation systems (Cerovska et al., 2013; Franconi et al., 2002; Marusic et al., 2001) to develop more 
immunogenic vaccines. E7GGGCP DNA induced a significantly higher cell-mediated response compared to 
vaccines based on E7GGG (Massa et al., 2008), showed greater reduction of TC-1* tumor cell growth, and 
enhanced survival in a therapeutic setting.  
In the present study, genetic and FP recombinants that encode the mutated non-oncogenic E6F47R and 
E7GGG proteins were fused to the 5’-terminus coding sequence of PVX-CP. The new recombinants were 
administered in homologous (DNA/DNA) and heterologous (DNA/FP) prime–boost vaccination regimens to 
improve the safety and efficacy of therapeutic vaccines against HPV16-related tumors.  
2. Materials and methods 
2.1. Cell lines 
Specific-pathogen-free primary chick embryo fibroblasts (CEFs) were grown in Dulbecco’s modified 
Eagle’s medium supplemented with 5% heat-inactivated calf serum (Gibco Life Technologies, Grand Island, 
NY, USA), 5% tryptose phosphate broth (Difco Laboratories, Detroit, MI, USA), and 100 U/ml penicillin 
and 100 mg/ml streptomycin. CaSki cells, which contain multiple copies of the integrated HPV16 DNA 
genome, green monkey kidney (Vero) cells, and normal human lung fibroblasts (MRC-5 cells) were grown 
in Dulbecco’s modified Eagle’s medium supplemented with 10% calf serum, and 100 U/ml penicillin and 
100 mg/ml streptomycin. TC-1 star (TC-1*), a clone of TC-1 cells (Venuti et al., 2009), generally used for 
challenge to test putative prophylactic or therapeutic vaccines in the preclinical mouse model, was selected 
for its 100% tumorigenicity in challenged mice. TC-1 cells are derived from primary epithelial cells of 
C57BL/6 mice, and cotransformed with the HPV16 E6 and E7 and by the activated c-Ha-ras oncogene (Lin 
et al., 1996). Before inoculation, the TC-1* cells were trypsinized and harvested, washed twice, and 
resuspended in Ca2+- and Mg2+-free phosphate-buffered saline (PBS-) at 5 ×105 cells/ml. 
 
2.2. Viruses 
The FP wild type (FPwt) and the FP-E6F47RCP, FP-E7GGGCP and FP-gagpol recombinants were amplified in 
CEFs, sucrose gradient purified, and titered before use. The FP recombinant containing the irrelevant gag 
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and pol genes of HIV-1 (FP-gagpol) (Radaelli et al., 2003) was used as a negative control for animal 
immunization.  
 
2.3. DNA-E6F47RCP and DNA-E7GGGCP expression plasmids 
DNA-E6F47RCP was constructed by fusion of the E6F47R gene in frame to the fourth codon of PVX-CP. The 
genes were assembled using splicing by overlap extension-polymerase chain reactions. For E6F47RCP fusion, 
the E6F47R gene was amplified using the forward E6BH3 (5’-GGC-CGG-ATC-CAA-GCT-TAT-CAT-GCA-
CCA-AAA-GAG-AAC-TGC-AAT-G-3’) and reverse CPE6 (5’-GGC-CTG-TGT-TGT-GCT-AGC-TGG-
CAG-CTG-GGT-TTC-TCT-TAC-G-3’) primers to incorporate the upstream part of PVX-CP and the 
downstream nucleotides of the E6 gene (5’-GGC-CTG-TGT-TGT-GCT-AGC-TGG-CAG-CTG-GGT-TTC-
TCT-TAC-G-3’). For CP amplification, the forward E6CP (5’-CGT-AGA-GAA-ACC-CAG-CTG-CCA-
GCT-AGC-ACA-ACA-CAG-GCC-3’) and reverse CPNP (5’-TTC-TCG-ACT-TGC-GGC-CGC-CTG-
CAG-TTA-TGG-TGG-TGG-TAG-AGT-GAC-3’) primers were used to incorporate the E6 gene 
downstream nucleotides. The assembled genes were cloned into the pcDNA3.1(+) mammalian expression 
vector after digestion with BamHI and NotI restriction enzymes, to obtain the DNA-E6F47RCP construct.  
All of the plasmids were propagated in E. coli XL1-Blue, prepared using EndoFree plasmid Maxi 
kits (Qiagen, Hilden, Germany), diluted in PBS-, and used for cell transfection or animal immunization. 
The preparation of the DNA-E7GGGCP was as already described by Massa et al. (Massa et al., 2008). 
 
2.4. Construction of the FP-E6F47RCP and FP-E7GGGCP recombinants  
FP-E6F47RCP and FP-E7GGGCP that expressed the E6F47RCP and E7GGGCP proteins were obtained by in-vitro 
homologous recombination (Pacchioni et al., 2010). Briefly, the genetically mutated E6F47RCP and E7GGGCP 
genes of HPV16 were obtained from the DNAE6F47RCP and DNAE7GGGCP plasmids, and were inserted into 
the pFPMCS vector downstream of the VVH6 Vaccinia virus early/late promoter. The pFPMCS vector 
contained the 3-β-hydroxysteroid dehydrogenase 5-delta 4 isomerase gene which was interrupted by a 
multiple cloning site (Rosel et al., 1986). The DNA sequences that encoded the E6F47RCP and E7GGGCP 
regions were verified using the forward V62 (5′-GGT-TCT-TGA-GGG-TTG-TGT 3′) and reverse V350 (5′-
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ATA-CAT-CGA-CCG-GTC-CAC 3′) primers for the E6F47RCP gene, and the forward V62 and reverse 
V101 (5′-CGA-AGC-TTT-TAT-GGT-TTC-TGA-GAA-CAG 3′) primers for the E7GGGCP gene. The 
amplification was carried out as described previously (Pozzi et al., 2009). The recombination plasmids were 
purified, and the E6F47RCP and E7GGGCP genes were sequenced to exclude any possible mutations, and 
designated as pFP-E6F47RCP (9403 bp) and pFP-E7GGGCP (9210 bp). The viral recombinants were obtained 
by in-vitro recombination in primary CEFs, as described previously (Radaelli and De Giuli Morghen, 1994), 
using FPwt and pFP-E6F47RCP or pFP-E7GGGCP (Zanotto et al., 2011). The recombinant clones were 
identified by autoradiography after plaque hybridization with the [32P]-labeled E6F47RCP and E7GGGCP 
probes, and then subjected to multiple cycles of plaque purification. One clone for each construct was 
selected for its correct and high expression of the E6F47RCP and E7GGGCP genes, as determined by RT-PCR, 
Western blotting and immunofluorescence. The FP-E6F47RCP and FP-E7GGGCP recombinants were 
amplified in CEFs, purified on a discontinuous sucrose gradient, titered, and used for mice immunization. 
 
2.5. Western blotting 
To determine whether the E6F47RCP and E7GGGCP proteins were correctly expressed, CEFs and Vero, NIH-
3T3 and MRC-5 cells were infected with 10 PFU/cell FP-E6F47RCP or FP-E7GGGCP and examined by 
Western blotting, as described previously (Pozzi et al., 2009). For E6, the blotted nitrocellulose membranes 
were incubated overnight at 4 °C with a primary anti-E6 rabbit polyclonal antibody (AbE6P/MI) produced 
in our laboratory, with 1:4000 dilution for CEFs, and 1:1000 dilution for Vero, MRC-5 and NIH-3T3 cells. 
AbE6P/MI was generated by multiple inoculations of New Zealand White rabbits with the FP-E6 
recombinant followed by E6 protein boosts. Before using, the serum was immmunoadsorbed overnight 
either with CEFs, Vero, MRC-5 or NIH-3T3 cells infected with FPwt. For E7, different monoclonal 
antibodies were used for the different cell lines: the 8C9 mouse anti-E7 monoclonal antibody (Zymed Lab., 
Invitrogen Corp., San Diego, CA) was used at 1:100-dilution for CEFs and Vero and MRC-5 cells. For the 
detection of E7GGGCP in the NIH-3T3 cell line, the ED17 mouse monoclonal antibody (AbE7/SC; Santa 
Cruz biotechnology, Santa Cruz, CA, USA) was used at 1:100 dilution. After a 1-h incubation with the 
secondary horseradish-peroxidase-conjugated anti-rabbit or anti-mouse goat antiserum (DakoCytomation, 
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Carpinteria, CA, USA) at 1:2000 dilution, and 2-h washes, the proteins were revealed using the ECL system 
(GE Healthcare, Buckinghamshire, UK). Cells infected with FPwt were used as the negative control, 
whereas CaSki cells, and the E6 and E7 proteins as positive controls. 
 
2.6. Immunofluorescence 
To detect the expression and intracellular localization of the E6F47RCP and E7GGGCP proteins, 
immunofluorescence was also carried out on CEFs and Vero, MRC-5, and NIH-3T3 cells infected with 10 
PFU/cell, as described previously (Zanotto et al., 2011). The cells were seeded at a density of 3-5 ×105/35-
mm2 dish on sterile glass coverslips, and grown overnight before infection with 10 PFU/cell of either FP-
E6F47RCP or FP-E7GGGCP, at 37 °C for 1 h. After an overnight incubation at 37 °C, the cells were washed 
twice with PBS-, fixed with 2% paraformaldehyde (Polysciences, Inc., Warrington, PA, USA) in PBS- for 
10 min, and then with 100% cold acetone for 5 min at 4 °C. For both E6 and E7, the rabbit polyclonal 
antibodies AbE6P/MI and AbE7P/MI were used for the different cell lines, followed by FITC-goat anti-
rabbit antiserum (DakoCytomation). AbE7P/MI was produced as already described for E6. Serum was used 
at 1:800 dilution in CEFs, and at 1:300 dilution in Vero and MRC-5 cells for detection of E6F47RCP, and at 
1:20 dilution for all of the cell lines for detection of E7GGGCP. The samples were viewed under a 
fluorescence microscope (Zeiss Axioskop). 
 
2.7. Production in bacteria of the E6 and E7 oncoproteins in their native form  
To obtain the HPV16 His6-E6 and His6-E7, the pQE30 expression plasmid (Qiagen) was engineered to 
contain the E6 or E7 genes (referred to as pQE30-E6/His or pQE30-E7/His, respectively), and inserted into 
the M15 strain of E. coli (Qiagen). The proteins were prepared under non-denaturing conditions. Briefly, 
after 16 h growth, the culture was 100-fold diluted in fresh Luria–Bertani broth with 25 μg/ml kanamycin 
and 100 μg/ml ampicillin, then incubated at 37 °C until 0.6-0.7 OD600 was reached. Expression of the His6-
E6 and His6-E7 proteins was induced with 1 mM isopropyl-β-D-thiogalactopyranoside. The cells were 
maintained at 28 °C or 30 °C (for His6-E6 and His6-E7, respectively) for 16 h, and harvested by 
centrifugation at 4000× g for 20 min at 4 °C. The pellet was resuspended in lysis buffer (50 mM NaH2PO4, 
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200 mM NaCl, with 100 μM dithiothreitol, pH 7.5, or 20 mM imidazole pH 8.0) that contained an EDTA-
free anti-protease cocktail (Roche, Basel, Switzerland), as recommended by the manufacturer. After adding 
1 mg/ml lysozyme and 1% Triton X-100, the cells were incubated for 1 h at 4 °C and sonicated on ice at a 
10-Hz output (1 min or 10 s for His6-E6 or His6-E7 respectively, thrice) with an ultrasonic disintegrator 
(Soniprep 150; MSE, London, UK). Clarification was by centrifugation at 15000× g for 45 min at 4 °C, and 
the supernatant was incubated for 16 h or 1 h (for His6-E6 or His6-E7, respectively) with 1 ml Ni-
nitrilotriacetic acid agarose resin (Ni-NTA, Qiagen), previously equilibrated in lysis buffer. After washing 
several times with 50 mM NaH2PO4, 200 mM NaCl, and 70 mM imidazole, to a final 0.01 OD280, the 
protein was eluted using 50 mM NaH2PO4, 200 mM NaCl, 300 mM imidazole, and run on 15% SDS-PAGE. 
All of the buffers used for the His6-E6 protein purification were at pH 7.5 and contained 100 μM 
dithiothreitol. The elution fractions enriched in the recombinant His6-E6 and His6-E7 proteins were pooled, 
quantified, and stored until use at 4 °C and -20 °C, respectively. The purified E6 (pE6) and E7 (pE7) 
proteins were dialyzed in PBS- containing either 0.02% betaine and 100 μM dithiothreitol for pE6, or 0.1 
mM ZnCl2 for pE7. Both proteins were used for the enzyme-linked immunosorbent assays (ELISA).  
 
2.8. Animal immunization  
Six-week-old female C57BL/6 mice were purchased from Charles River (Como, Italy) and maintained under 
specific pathogen-free conditions at the Experimental Animal Department of the Regina Elena Cancer 
Institute (Rome, Italy).  
Two therapeutic prime–boost protocols were performed: the first using only genetic immunogens, 
and the second using combined genetic/FP recombinant vaccines. In the first protocol (Fig. 1A), four groups 
of five mice were inoculated by subcutaneous injection (s.c.) in the flank with 5 ×104 TC-1* tumor 
cells/mouse, and vaccinated after 3 days and 10 days. Immunization was performed i.m. with 100 µg/mouse 
of each recombinant DNA (protocol G1: DNA-E6F47RCP; protocol G2: DNA-E7GGGCP; protocol G3: DNA-
E6F47RCP + DNA-E7GGGCP). The mice for protocol G4 were mock vaccinated and used as controls. In the 
second protocol (Fig. 1B), after TC-1* tumor cell inoculation, the mice of G1, G2, and G3 (five mice/group) 
were primed once after 3 days with the same plasmids used in the genetic vaccination, and boosted s.c. at 1 
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week and 2 weeks after the priming with 107 PFU/mouse of each FP recombinant (protocol G1: FP-
E6F47RCP; protocol G2: FP-E7GGGCP; protocol G3: FP-E6F47RCP + FP-E7GGGCP). A group of mice was 
vaccinated with the DNA and FP recombinants that contained the unrelated gag and pol transgenes as a 
negative control (protocol G4: DNA-gagpol, 100 μg/mouse, i.m.; FP-gagpol, 2 ×107 PFU/mouse, s.c.). 
Tumor growth was monitored by visual inspection and palpation three times a week. Tumor size was 
measured with calipers, and the volume estimated using the formula (width2 × length × 0.5). The mice were 
euthanized for ethical reasons when tumors reached a volume of about 4 cm3.  
The protocols were approved by the Ethical Committee and were developed according to European 
Guidelines no. 86/609/CEE and 116/92 for the protection of laboratory experimental animals and laboratory 
animal care (Ministry of Health, Department of Veterinary Public Health, Nutrition and Food Security, 
Protocol 17/2006). 
 
2.9. ELISA 
The ELISA was essentially performed as described previously (Bissa et al., 2013), using the purified native 
HPV16 E6 or E7 proteins, and CaSki cells or MRC-5 cells (negative control) as plate-bound antigens. 
Briefly, 96-well maxisorp microtiter plates (Nunc, Naperville, IL, USA) were coated with pE6 or pE7 (300 
ng/well) in PBS-, or with CaSki or MRC-5 lysates (105 cells/well) in 0.05 M carbonate–bicarbonate buffer, 
pH 9.6, and incubated overnight at 4 °C. The CaSki and MRC-5 cells were disrupted by freeze–thawing 
three times. The sera of the animals were examined separately and used at 1:50 and 1:100 dilutions, and the 
binding was revealed using horseradish-peroxidase-conjugated goat anti-mouse sera at 1:2000 dilution 
(DakoCytomation) and tetramethylbenzidine substrate (Sigma-Aldrich Italia, Milan, Italy). The absorbance 
for each well was measured at 450 nm with a microplate reader 550 (Bio-Rad Laboratories, Hercules, CA, 
USA). 
 
2.10. Statistical analyses 
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Statistical analyses were performed using one-way ANOVA parametric tests and Bonferroni analysis of 
variance, using the GraphPad Prism 5 software. Statistical significance was set as p <0.05 (*), p <0.01 (**), 
p <0.001 (***).  
 
3. Results  
 
3.1. FP-E6F47RCP and FP-E7GGGCP recombinants express the modified E6 and E7 transgenes fused to CP 
Fusion of the mutated E6F47R (506 bp) and E7GGG (326 bp) genes to the CP gene (732 bp) generated the 
expected bands of 1179 bp and 999 bp that corresponded to the E6F47RCP and E7GGGCP genes, respectively 
(data not shown). The genetically mutated E6F47RCP and E7GGGCP genes inserted into the FP vectors by in-
vitro homologous recombination expressed the mutated fusion proteins in all of the infected CEF and Vero, 
MRC-5 and NIH-3T3 cell lysates, as demonstrated by Western blotting. These showed as a 43-kDa protein 
band for E6F47RCP (Fig. 2A, I, lanes 2) and a 40-kDa protein band for E7GGGCP (Fig. 2, II, lanes 2). No 
specific bands were seen when these cells were infected with FPwt (Fig. 2A, I and II, lanes 1). The non-
mutated His6-E6 and His6-E7 proteins produced by an engineered bacterial vector were used as positive 
controls (Fig. 2A, I and II, lanes 3).  
 
3.2. E6 and E7 expressed by FP-E6F47RCP and FP-E7GGGCP are mainly in the cytoplasm  
FP-E6F47RCP (Fig. 2B; 1b-4b) and FP-E7GGGCP (Fig. 2B; 1c-4c) recombinants were also used to infect 
CEFs and Vero, MRC-5 and NIH-3T3 cells, to determine by immunofluorescence the cellular localization of 
the E6 and E7 proteins. The E6 and E7 staining was mainly cytoplasmic and diffuse in CEFs (Fig. 2B; 1b 
and 1c), but granular in the mammalian cell lines (Fig. 2B; 2b-4b, 2c-4c). The immunofluorescence was 
similar to that observed in the same cells infected with FP-E6F47R and FP-E7GGG (data not shown). The 
intensities of the fluorescence signals were also greater for E6 than for E7. The FPwt-infected cells were 
always negative, as expected (Fig. 2B; 1a-4a).  
 
 13    
3.3. Tumor appearance and development were more delayed when DNA-E6F47RCP and DNA-E7GGGCP were 
administered in combination 
After the genetic immunization (Fig. 3; see Fig. 1A for protocol groups), when DNA-E6F47RCP was 
compared to DNA-E7GGGCP, and both the immunogens were used either alone or in combination, 100% of 
the G4 mock-immunized mice developed tumors at day 14 post-inoculation (p.i.). Conversely, tumor 
appearance was significantly delayed to day 19 p.i. (p <0.05) in 100% of the mice of the G1 and G2 groups.   
In the G3 group, tumor bearing mice, defined as the animals carrying a palpable tumor, were 80% at day 19 
p.i. (p <0.05) and reached 100% of the mice by day 24 p.i..  
At 24 days p.i., the tumor volumes of the G1, G2, and G3 mice were smaller compared to those of the G4 
mice (Table 1, p <0.001; see Fig. 1A for protocol groups). Moreover, when DNA-E6F47RCP and DNA-
E7GGGCP were administered in combination, the tumor volumes were also reduced, and were significantly 
smaller if compared to when DNA-E6F47RCP was used alone (G3 vs G1, p <0.05). After a week, the tumor 
volumes in all of the groups were further increased, and the mice were euthanized for ethical reasons.  
 
3.4. Genetic/FP vaccines seem to give better results when the immunogens are used alone 
After the genetic/FP recombinant immunizations (Fig. 4; see also Fig. 1B for protocol groups), when 
priming was performed with the single (E6F47RCP or E7GGGCP) or combined (E6F47RCP + E7GGGCP) DNA 
vaccines, followed by two boosts with the single or combined FP recombinants, tumors developed in 20% of 
G4 mice at day 12 p.i., reaching 40% by day 14, 80% by day 17 p.i. and 100% by day 28. Unexpectedly, a 
similar trend was observed in the animals of G3, that developed tumors at day 12 p.i. in 20% of the animals, 
reaching 100% by day 17 p.i.. Conversely, a delay in tumor appearance was observed in the G1 and G2 
mice. In G1, the tumors first appeared in 60% of the mice at day 17 p.i., and in 100% of the animals by day 
28 p.i. whereas in G2 tumor bearing animals were 20% at day 14 p.i., then reaching 60% at day 17 p.i., and 
100% only by day 38 p.i.. At 33 days p.i., the tumor volumes were similar in G1 and G2, and much larger in 
G3 (data not shown).   
 
3.5. The specific humoral response is almost undetectable 
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Mice immunized by the combined genetic/FP recombinants were tested for anti-E6-specific or anti-E7-
specific humoral immunity. The antibody responses against the E6 and E7 proteins were determined by 
ELISA, with plates coated with either the purified native pE6 or pE7 proteins, or the CaSki cell lysates (Fig. 
5). The MRC-5 cell lysates were used as a negative-control antigen. The mice sera were analyzed before 
injecting the TC-1* cells (T0), before the first and second boosts (T1, T2, respectively), and 1 week after the 
second boost (T3). The results are reported only after the third immunization (T3), as the means from each 
group of mice. By using the different plate-bound antigens, no clear differences in the humoral responses 
were found among the groups. Also when E7 or the CaSki cells were used, the observed response was very 
limited. 
 
4. Discussion 
Around 5% of all human cancers are related to HPV (Rosales, R. and  Rosales, C., 2014), but no treatment is 
presently available to eliminate already established infections and prevent or delay disease recurrence. A 
therapeutic vaccine that targets the E6 and E7 oncoproteins might clear HPV malignancies by eliciting 
specific cytotoxic T-lymphocyte immune responses (Lin et al., 2010). This would also overcome the 
problem of the high numbers of HPV-infected subjects who might develop tumors of the cervix. 
Vector design and antigen expression greatly influence the immunogenicity and efficacy of recombinant 
DNA and viral vaccines. To improve the antitumor immune responses, both DNA and recombinant viral 
vaccines have already been widely investigated, in attempts to combine efficacy with safety, 
immunogenicity, and low cost of production. Given the promising results obtained in vivo by the genetic 
E7GGGCP vaccine (Massa et al., 2008), a novel E6F47RCP DNA construct was generated by fusing the 
attenuated HPV16 E6F47R gene with the PVX-CP gene. This plant virus CP represents a dominant pathogen-
derived antigen and an innovative way to enhance the immunogenicity of the encoded product, as it 
increases the Th1 response (Massa et al., 2008; Savelyeva et al., 2001; Savelyeva et al., 2003) and reduces 
inappropriate immune responses and autoimmunity in therapeutic vaccination regimens.  
In the present study, we demonstrated that: (i) FP-E6F47RCP and FP-E7GGGCP recombinants can 
correctly express the transgenes fused to CP in cell lines of different species; (ii) after the genetic 
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immunization, tumor appearance was delayed up to day 19 p.i. and tumor volume was lower at 24 days p.i. 
than in the control mice; (iii) after the heterologous DNA/FP vaccination strategy, better results were 
obtained with the single immunogens.  
After generating the FP-E6F47RCP and FP-E7GGGCP recombinants, the transgene expression was 
evaluated in replication-permissive CEFs and non-permissive Vero, MRC-5 and NIH-3T3 cells by Western 
blotting and immunofluorescence. The analysis by Western blotting confirmed that all of the cell lines 
correctly expressed the recombinant proteins. In non-permissive cell lines, higher concentrations of antibody 
had to be used to reveal the E6F47RCP protein, potentially because of low protein expression. In particular, in 
MRC-5 cells, the specific band was only visible when using larger amounts of cell lysate. The intensity of 
the bands was therefore not comparable because of the different conditions used in the different cell lines, 
including the different antibodies, dilutions, amounts of cell lysate, and lengths of film exposure. The 
presence of CP does not appear to modify the expression of E6 and E7, as there were similar 
immunofluorescence intensities when FP-E6F47RCP-infected and FP-E7GGGCP-infected cells were compared 
to cells infected with FP-E6F47R and FP-E7GGG, which express E6 and E7 with no CP. The E6 and E7 
cellular localization was mainly in the cytoplasm in all of the cell lines, as expected for foreign proteins 
synthesized by avipoxviral vectors. Interestingly, the E6 polyclonal antibody used for Western blotting also 
recognized the protein using immunofluorescence, thus demonstrating that it can detect both the native and 
denatured forms of the protein. Conversely, the E7 polyclonal antibody revealed the protein by Western 
blotting but not by immunofluorescence, thus showing its binding only to non-conformational epitopes. 
After inoculation of the TC-1* tumor cells, the number of healthy animals was higher with 
administration of the DNA/DNA vaccines rather than the DNA/FP vaccines. A significant delay in tumor 
growth was observed in the mice following the DNA/DNA immunizations than could not be observed after 
the DNA/FP regimen. When the E6 and E7 DNA recombinants were administered in combination, tumor 
appearance was delayed, and when tumors developed their volumes were significantly smaller compared to 
the controls, which may be ascribed to the vaccine-induced cytotoxic T-lymphocyte response. Conversely, 
after the heterologous combined DNA/FP strategy, an improved protection against tumor development and 
growth were obtained with the single immunogens. In spite of the apparent contradictions in the results 
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obtained by the two protocols, this could be due to the double administration of DNA in the “genetic” 
immunization before boosting with FP recombinants. 
As for the humoral response, poor antibody responses to certain antigens have already been described for the 
C57BL/6 mouse strain of mice (Mols-Vorstermans et al., 2013; Sellers et al., 2011), which showed an 
aspecific and elevated baseline response, that prevented the detection of specific antibodies. If this is 
expected using DNA vaccines, which appear to mainly elicit cell-mediated immunity, a response should be 
present after the boost with the FP recombinants.  
The present study also confirms the data from our previous research where similar results were obtained 
after immunizing mice with only the DNA E6F47RCP and E7GGGCP vaccines by electroporation (Cordeiro et 
al., 2015). In contrast to that study, most of the mice remained tumor-free up to day 19 p.i.., instead of 13 
days p.i., 
which can be ascribed to the different inoculation systems and the use of the different tumor cells for 
challenge.  
The aim of this study was to verify the immunogenicity and efficacy of viral-vectored vaccines and 
the best association of the immunogens able to delay tumor appearance and growth, after fusing E6F47R and 
E7GGG to the CP of Potato virus X. It was also our aim to use the genetic and FP-based E6F47RCP and 
E7GGGCP recombinants in combination, which was not previously performed. In fact, it is already known 
that, although convenient because of their low cost and safety, DNA vaccines are poorly immunogenic in 
humans, and the use of FP-vectored vaccines as a boost could improve the efficacy. Although the combined 
genetic/FP strategy improved the outcome only when E6F47RCP and E7GGGCP were separately administered, 
the use of this regimen for E6F47RCP and in particular for E7GGGCP was able to delay tumor appearance in a 
higher number of animals than by the genetic immunization used alone. 
Although the limited animal number used in this study might have prevented better statistical evaluations, 
the results of these immunization regimens suggest that the next strategy should include a repeated DNA 
administration by electroporation, which also reduces the amount of the vaccine antigen. It is also well 
known that the route of administration and vaccine dosage can affect immunogenicity (Bansal et al., 2008), 
as also shown by the improved immunological responses induced in mice by intranasal/oral immunization, 
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rather than the i.m. or s.c. routes (Lu et al., 2011). Given the advantages of mucosal vaccine delivered by 
aerosol, this way of immunization with recombinant avipoxvirus-based vaccines might improve 
immunogenicity and protection. Administration by the intratumoral route to deliver the transgenes directly 
into the tumor mass and fusion to the already tested adjuvants, such as the detoxified form of the saporin 
plant enzyme SAP-KQ (Massa et al., 2011), might also ameliorate immunogenicity and efficacy. 
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Figure legends 
 
Fig. 1. Therapeutic immunization protocols.  
(A) For the genetic vaccination regimen, four groups of five mice/group were injected s.c. with 5 ×104 TC-
1* tumor cells/mouse and the immunogens (100 µg/mouse of each recombinant DNA) were administered 
i.m. 3 days and 10 days after TC-1* inoculation. The mice for protocol G4 were mock vaccinated and used 
as controls. (B) For the genetic/FP protocol, five mice/group were injected s.c. with 5 ×104 TC-1* cells, 
primed once i.m. after 3 days with recombinant DNA, and boosted s.c. (107 PFU/mouse of each FP 
recombinant) 1 week and 2 weeks after priming. The mice for protocol G4 were vaccinated with DNA and 
FP recombinants containing the unrelated gag and pol transgenes as a negative control. Arrows, times of 
TC-1* inoculation and vaccine administration; black triangles (T0-T3), bleeding times. 
 
Fig. 2. WB analysis and cellular localization of E6F47RCP and E7GGGCP proteins expressed by the FP 
recombinants.  
CEFs and Vero, MRC-5, and NIH-3T3 cells were infected at 10 PFU/cell with the FP-E6F47RCP and FP-
E7GGGCP viral recombinants. The cell lysates were examined by Western blotting using the rabbit 
polyclonal AbE6P/MI antibody for the detection of E6 (2A, I, lanes 2), whereas different mouse monoclonal 
antibodies were used for the different cell lines for the detection of E7 (2A, II, lanes 2). The bands were 
revealed by horseradish-peroxidase-conjugated anti-rabbit or anti-mouse goat antiserum. The native E6 (2A, 
I, lane 3) and E7 (2A, II, lane 3) proteins were used as the positive controls (C+). No specific proteins were 
seen when the cells were infected with FPwt (2A, I and II, lanes 1).  
CEFs and Vero, MRC-5, and NIH-3T3 cells were infected with the FP-E6F47RCP (2B, 1b-4b) and FP-
E7GGGCP (2B, 1c-4c) recombinants to determine the intracellular localization of the transgene products. 
Cytoplasmic staining was observed in all of the cell lines, as mainly diffuse in the CEFs (2B, 1b, 1c) and 
granular in the mammalian cells (2B, 2b-4b, 2c-4c). Rabbit polyclonal antibodies produced in our laboratory 
were used at different dilutions for the different cell lines: AbE6P/MI was used for E6, and AbE7P/MI for 
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E7, both followed by FITC-goat anti-rabbit antiserum. The immunofluorescence was greater for E6 than for 
E7, and was not seen when FPwt-infected cells were treated with anti-E6 or anti-E7 antibodies (2B, 1a-4a). 
 
Fig. 3. Tumor bearing mice after the genetic therapeutic immunization.  
C57BL/6 mice were injected s.c. with 5 ×104 syngeneic TC-1* tumor cells and immunized 3 days and 10 
days later (p.i.), according to the group protocols shown in Fig. 1. Priming was performed on day 3 p.i. with 
single DNA-E6F47RCP (G1) or DNA-E7GGGCP (G2) or combined DNA-E6F47RCP + DNA-E7GGGCP (G3) 
genetic vaccines, followed by a boost on day 10 p.i. with single (G1 or G2) or combined (G3) genetic 
vaccines. Mice of G4 were mock vaccinated and used as controls, and they all developed tumors at day 14 
p.i.. Conversely, tumor appearance in the vaccinees was significantly delayed to day 19 p.i. (G1, G2, G3, p 
<0.05). The animals carrying a palpable tumor were defined as tumor bearing animals. 
 
Fig. 4. Tumor-bearing mice after DNA/FP recombinant immunizations.  
C57BL/6 mice were inoculated with syngeneic TC-1* tumor cells and immunized 3 days, 10 days and 17 
days later (p.i.), as shown in Fig. 1B. Priming was performed with single (E6F47RCP or E7GGGCP; G1 or G2) 
or combined (E6F47RCP + E7GGGCP; G3) genetic vaccines on day 3 p.i., followed by two boosts with single 
(G1 and G2) or combined (G3) FP recombinants on days 10 and 17 p.i.. Mice of G4, vaccinated with DNA 
and FP recombinants containing the gag and pol unrelated genes, developed tumors by day 12 p.i., reaching 
100% by day 28 p.i.. Conversely, a delay was observed in G1, where tumors first appeared by day 17, 
reaching 100% of the animals by day 28 p.i., and in G2, where tumors first appeared by day 14, reaching 
100% by day 38 p.i.. In the animals of G3, tumors developed following a trend similar to the control mice of 
the G4 group. 
 
Fig. 5. Analysis of the E6-specific and E7-specific humoral responses in mice immunized with the 
genetic/FP recombinants.  
Anti-E6 and anti-E7 antibody titers were determined by ELISA using either the native purified recombinant 
pE6 and pE7 proteins or CaSki cell lysates as plate-bound antigens. MRC-5 cell lysates were also plated as a 
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negative control. Data are reported as the means of the absorbance values using the sera of each group of 
mice after the third immunization. No clear differences in the humoral responses were found among the 
groups by using the different antigens and the results were very limited.  
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Table 1. Tumor volumes at 24 days p.i. in mice vaccinated with the DNA genetic recombinants 
 
Vaccination 
protocol 
Mean tumor volume (cm3) 
24 days p.i. 
G1 1.71 
G2 1.07 
G3     0.53** 
G4       3.19*** 
p.i., post inoculation 
**, p<0.05,G3 versus G1 
***, p<0.001, G1, G2, G3 versus G4 
 
